期刊文献+

Long-term dexamethasone treatment diminishes store-operated Ca^(2+) entry in salivary acinar cells 被引量:1

Long-term dexamethasone treatment diminishes store-operated Ca^(2+) entry in salivary acinar cells
下载PDF
导出
摘要 Corticosteroids are used in the treatment of many diseases; however, they also induce various side effects. Dexamethasone is one of the most potent corticosteroids, and it has been reported to induce the side effect of impaired salivary gland function. This study aimed to evaluate the effects of dexamethasone on mouse submandibular gland function to gain insight into the mechanism of dexamethasone-induced salivary hypofunction. The muscarinic agonist carbachol(CCh) induced salivary secretion and was not affected by short-term dexamethasone treatment but was decreased following long-term dexamethasone administration. The expression levels of the membrane proteins Na^+-K^+-2 Cl-cotransporter, transmembrane member 16 A, and aquaporin 5 were comparable between the control and long-term dexamethasone treatment groups. The CCh-induced increase in calcium concentration was significantly lower in the presence of extracellular Ca^(2+) in the long-term dexamethasone treatment group compared to that in the control group. Furthermore, CCh-induced salivation in the absence of extracellular Ca^(2+) and Ca^(2+) ionophore A23187-induced salivation was comparable between the control and long-term dexamethasone treatment groups.Moreover, salivation induced by the Ca^(2+) -ATPase inhibitor thapsigargin was diminished in the long-term dexamethasone treatment group. In summary, these results demonstrate that short-term dexamethasone treatment did not impair salivary gland function, whereas long-term dexamethasone treatment diminished store-operated Ca^(2+) entry, resulting in hyposalivation in mouse submandibular glands. Corticosteroids are used in the treatment of many diseases; however, they also induce various side effects. Dexamethasone is one of the most potent corticosteroids, and it has been reported to induce the side effect of impaired salivary gland function. This study aimed to evaluate the effects of dexamethasone on mouse submandibular gland function to gain insight into the mechanism of dexamethasone-induced salivary hypofunction. The muscarinic agonist carbachol(CCh) induced salivary secretion and was not affected by short-term dexamethasone treatment but was decreased following long-term dexamethasone administration. The expression levels of the membrane proteins Na^+-K^+-2 Cl-cotransporter, transmembrane member 16 A, and aquaporin 5 were comparable between the control and long-term dexamethasone treatment groups. The CCh-induced increase in calcium concentration was significantly lower in the presence of extracellular Ca^(2+) in the long-term dexamethasone treatment group compared to that in the control group. Furthermore, CCh-induced salivation in the absence of extracellular Ca^(2+) and Ca^(2+) ionophore A23187-induced salivation was comparable between the control and long-term dexamethasone treatment groups.Moreover, salivation induced by the Ca^(2+) -ATPase inhibitor thapsigargin was diminished in the long-term dexamethasone treatment group. In summary, these results demonstrate that short-term dexamethasone treatment did not impair salivary gland function, whereas long-term dexamethasone treatment diminished store-operated Ca^(2+) entry, resulting in hyposalivation in mouse submandibular glands.
出处 《International Journal of Oral Science》 SCIE CAS CSCD 2019年第1期25-32,共8页 国际口腔科学杂志(英文版)
基金 supported by a grant from the Japan Society for the Promotion of Science KAKENHI (No. 17K17184)
  • 相关文献

参考文献1

二级参考文献40

  • 1Trence DL. Management of patients on chronic glucocorticoidtherapy: an endocrine perspective. Prim Care 2003; 30: 593-605#[PMID: 14692203 DOI: 10.1016/s0095-4543(03)00038-1].
  • 2Tamez Perez HE, Gómez de Ossio MD, Quintanilla Flores DL,Hernández Coria MI, Tamez Pe-a AL, Cuz Pérez GJ, ProskauerPe-a SL. Glucose disturbances in non-diabetic patients receivingacute treatment with methylprednisolone pulses. Rev AssocMed Bras 2012; 58: 125-128 [PMID: 22392327 DOI: 10.1016/s0104-4230(12)70165-3].
  • 3Ha Y, Lee KH, Jung S, Lee SW, Lee SK, Park YB. Glucocorticoidinduceddiabetes mellitus in patients with systemic lupuserythematosus treated with high-dose glucocorticoid therapy. Lupus2011; 20: 1027-1034 [PMID: 21659423 DOI: 10.1177/0961203311402246].
  • 4van Raalte DH, Ouwens DM, Diamant M. Novel insights intoglucocorticoid-mediated diabetogenic effects: towards expansionof therapeutic options- Eur J Clin Invest 2009; 39: 81-93 [PMID:19200161 DOI: 10.1111/j.1365-2362.2008.02067].
  • 5Sch-cke H, D-cke WD, Asadullah K. Mechanisms involved in theside effects of glucocorticoids. Pharmacol Ther 2002; 96: 23-43[PMID: 12441176 DOI: 10.1016/s0163-7258(02)00297-8].
  • 6Hirsch IB, Paauw DS. Diabetes management in special situations.Endocrinol Metab Clin North Am 1997; 26: 631-645 [PMID:9314019 DOI: 10.1016/s0889-8529(05)70271-1].
  • 7Tamez-Perez HE, Gutierrez-Hermosillo H, Cedillo-RodriguezJA, Mora-Torres N, Hernandez-Coria M, Gomez-de-Osio M.Tratamiento con insulina en el paciente hospitalizado con diabetesmellitus tipo 2 única opción- Med Int Mex 2007; 23:196-199.
  • 8Braithwaite SS, Barr WG, Rahman A, Quddusi S. Managingdiabetes during glucocorticoid therapy. How to avoid metabolicemergencies. Postgrad Med 1998; 104: 163-166, 171, 175-176[PMID: 9823393 DOI: 10.3810/pgm.1998.11.426].
  • 9Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA.Prevalence and predictors of corticosteroid-related hyperglycemiain hospitalized patients. Endocr Pract 2006; 12: 358-362 [PMID:16901792 DOI: 10.4158/ep.12.4.358].
  • 10Ca-da- DN, Pa- FA, Cakal E. Glucocorticoid-induced diabeticketoacidosis in acute rheumatic fever. J Cardiovasc PharmacolTher 2008; 13: 298-300 [PMID: 19087951 DOI: 10.1177/1074248408326609].

共引文献14

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部